


PHARMACEUTICAL 2019

AXIM BIOTECHNOLOGIES INC. Rank 319 of 371





PHARMACEUTICAL 2019

AXIM BIOTECHNOLOGIES INC. Rank 319 of 371

The relative strengths and weaknesses of AXIM BIOTECHNOLOGIES INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of AXIM BIOTECHNOLOGIES INC. compared to the market average is the variable Liabilities, Non-Current, increasing the Economic Capital Ratio by 307% points. The greatest weakness of AXIM BIOTECHNOLOGIES INC. is the variable Assets, Current, reducing the Economic Capital Ratio by 253% points.

The company's Economic Capital Ratio, given in the ranking table, is -665%, being 334% points below the market average of -331%.

Input Variable	Value in 1000 USD
Assets, Current	2,023
Cost of Goods Sold	8.5
Intangible Assets	54
Liabilities, Current	3,324
Liabilities, Non-Current	4,847
Other Assets	7.4
Other Compr. Net Income	0
Other Expenses	3.4
Other Liabilities	0
Other Net Income	-1,719
Property and Equipment	5.6
Research and Development	2,056
Revenues	196
Selling, General and Administrative Expense	3,164

Output Variable	Value in 1000 USD
Assets	2,089
Liabilities	8,171
Expenses	5,232
Stockholders Equity	-6,082
Net Income	-6,755
Comprehensive Net Income	-6,755
Economic Capital Ratio	-665%